Tianxia Lan
Impact in
- Immunology top 5%
- Immune cells in cancer
- Immunotherapy and Immune Responses
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
Papers in
- Immunology 11
- Immunotherapy and Immune Responses 7
- Immune cells in cancer 3
- Immune Response and Inflammation 3
- Oncology 9
- Cancer Immunotherapy and Biomarkers 2
- Cancer Cells and Metastasis 2
- CAR-T cell therapy research 2
- Co-authors
- Xiawei Wei (16 shared papers)Min Luo (6 shared papers)Xiawei Wei (3 shared papers)Minyang Fu (2 shared papers)Yuquan Wei (6 shared papers)Kun‐Liang Guan (1 shared paper)Yuan Hu (1 shared paper)Ting Luo (1 shared paper)
- Journals
- Signal Transduction and Targeted Therapy (4 papers)Acta Pharmaceutica Sinica B (2 papers)Cancer Letters (1 paper)Advanced Science (1 paper)Journal of Hematology & Oncology (1 paper)
- Partner nations
- ChinaJapanUnited States
In The Last Decade
Tianxia Lan
23 papers receiving 1.7k citations
Tianxia Lan's Hit Papers
Peers
Comparison fields: 5 of 101
- Immunology 419
- Oncology 362
- Cell Biology 235
- Cancer Research 158
- Genetics 105
Countries citing papers authored by Tianxia Lan
This map shows the geographic impact of Tianxia Lan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tianxia Lan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tianxia Lan more than expected).
Fields of papers citing papers by Tianxia Lan
This network shows the impact of papers produced by Tianxia Lan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tianxia Lan. The network helps show where Tianxia Lan may publish in the future.
Co-authors
The 25 scholars most cited alongside Tianxia Lan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 23 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | The Hippo signalling pathway and its implications in human health and diseases Hit paper breakdown → | 2022 | 414 |
| 2 | Mesenchymal stem/stromal cells in cancer therapy Hit paper breakdown → | 2021 | 250 |
| 3 | CCL5/CCR5 axis in human diseases and related treatments Hit paper breakdown → | 2021 | 218 |
| 4 | Tumor-associated neutrophils and neutrophil-targeted cancer therapies Hit paper breakdown → | 2022 | 206 |
| 5 | 2021 | 166 | |
| 6 | 2022 | 80 | |
| 7 | 2022 | 60 | |
| 8 | 2023 | 43 | |
| 9 | 2021 | 38 | |
| 10 | 2022 | 32 | |
| 11 | 2023 | 25 | |
| 12 | 2022 | 22 | |
| 13 | 2022 | 22 | |
| 14 | 2022 | 20 | |
| 15 | 2024 | 20 | |
| 16 | 2021 | 16 | |
| 17 | 2024 | 16 | |
| 18 | 2021 | 8 | |
| 19 | 2024 | 5 | |
| 20 | 2024 | 5 |
About Tianxia Lan
Tianxia Lan is a scholar working on Immunology, Oncology, Molecular Biology, Infectious Diseases and Pulmonary and Respiratory Medicine, having authored 23 papers that have together received 1.7k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (7 papers), SARS-CoV-2 and COVID-19 Research (5 papers), Immune cells in cancer (3 papers), Immune Response and Inflammation (3 papers), RNA Interference and Gene Delivery (2 papers), Cancer Immunotherapy and Biomarkers (2 papers), Cancer Cells and Metastasis (2 papers) and CAR-T cell therapy research (2 papers). The work is most often cited by research in Immunology (419 citations), Oncology (362 citations), Cell Biology (235 citations), Cancer Research (158 citations) and Genetics (105 citations). Tianxia Lan has collaborated with scholars based in China, Japan and United States. Frequent co-authors include Xiawei Wei, Min Luo, Xiawei Wei, Minyang Fu, Yuquan Wei, Kun‐Liang Guan, Yuan Hu, Ting Luo, Li Chen and Zhen Zeng. Their work appears in journals such as Signal Transduction and Targeted Therapy, Acta Pharmaceutica Sinica B, Cancer Letters, Advanced Science and Journal of Hematology & Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.